A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans

Blood

Volumn 92, Issue 5, 1998, Pages 1518-1525

  Bossavy, Jean Pierre ^b   Thalamas, Claire ^b   Sagnard, Luc ^b   Barret, André ^b   Sakariassen, Kjell ^b   Boneu, Bernard ^b   Cadroy, Yves ^a  

^a CHU PURPAN   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; COLLAGEN; FIBRIN; PLACEBO; THROMBOPLASTIN; TICLOPIDINE;

ADULT; ARTERY THROMBOSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FIBRIN DEPOSITION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHEAR RATE; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

EID: 0032170080     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.5.1518.417k22_1518_1525     Document Type: Article

References (36)

1. Hirsh J, Dalen JE, Fuster V, Harker LA, Patrono C, Roth G: Aspirin and other plate let-active drugs. The relationship among dose, effectiveness, and side effects. Chest 108:2475, 1995 (suppl)
2. Herbert JM, Bernat A, Samama M, Maffrand JP: The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat. Thromb Haemost 76:94, 1996
3. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084, 1996
4. Sakariassen KS, Aarts PAMM, de Groot PG, Houdijk WPM, Sixma JJ: A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 102:522, 1983
5. Sakariassen KS, Joss R, Muggli R, Kuhn H, Tschopp TB, Sage H, Baumgartner HR: Collagen type III induced ex vivo thrombogenesis in humans: Role of platelets and leucocytes in deposition of fibrin. Arteriosclerosis 10:276, 1990
6. Orvim U, Roald HE, Stephens RW, Rocs N, Sakariassen KS: Tissue factor-induced coagulation triggers platelet thrombus formation as efficiently as fibrillar collagen at arterial blood flow condition. Arterioscler Thromb 14:1976, 1994
7. Diquélou A, Lemozy S, Dupouy D, Boneu B, Sakariassen KS, Cadroy Y: Effect of blood flow on thrombin generation is dependent on the nature of thrombogenic surface. Blood 84:2206, 1994
8. Bossavy JP, Sakariassen KS, Barret A, Boneu B, Cadroy Y: A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis. Thromb Haemost 79:162, 1998
9. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ: Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95:594, 1997
10. van Zanten GH, de Graaf S, Slootweg PJ, Heijnen HFG, Connolly TM, de Groot PG, Sixma JJ: Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest 93:615, 1994
11. Sakariassen KS, Cousot D, Hadvary P, Baumgartner HR: Aspirin ingestion reduces thrombus volume in human nonanticoagulated blood only at shear rates characteristic for stenosed arteries. Thromb Haemost 65:782, 1991 (abstr)
12. Roald HE, Orvim U, Bakken IJ, Barstad RM, Kierulf P, Sakariassen KS: Modulation of thrombotic responses in moderately stenosed arteries by cigarette smoking and aspirin ingestion. Arterioscler Thromb 14:617, 1994
13. Roald HE, Barstad RM, Engen A, Kierulf P, Skjorten F, Sakariassen KS: HN-11500-A novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb Haemost 71:103, 1994
14. Roald HE, Barstad RM, Kierulf P, Skjorten F, Dickinson JP, Kieffer G, Sakariassen KS: Clopidogrel-A platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost 71:103, 1994
15. Baumgartner HR, Muggli R: Adhesion and aggregation: Morphological demonstration and quantitation in vivo and in vitro, in Gordon JE (ed): Platelets in Biology and Pathology. Amsterdam, Netherlands, Elsevier/North-Holland, 1976, p 23
16. Diquélou A, Dupouy D, Gaspin D, Constans J, Sié P, Boneu B, Sakariassen KS, Cadroy Y: Relationship between endothelial tissue factor and thrombogenesis under blood flow conditions. Thromb Haemost 74:778, 1995
17. Orvim U, Barstad RM, Stormorken H, Brosstad F, Sakariassen KS: Immunologic quantification of fibrin deposition in thrombi formed in flowing native human blood. Br J Haematol 95:389, 1996
18. Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G, Ferraro M, Colombo A: A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 93:215, 1996
19. Albiero R, Hall P, Itoh A, Blengino S, Nakamura S, Martini G, Ferraro M, Colombo A: Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation 95:1145, 1997
20. More RS, Chauhan A: Antiplatelet rather than anticoagulant therapy with coronary stenting. Lancet 349:146, 1997
21. Karillon GJ, Morice MC, Benveniste E, Bunouf P, Aubry P, Cattan S, Chevalier B, Commeau P, Cribier A, Eiferman C, Grollier G, Guerin Y, Henry M, Lefebvre T, Livarek B, Louvard Y, Marco J, Makowski S, Monassier JP, Pernes JM, Rioux P, Spaulding C, Zemour G: Intracoronary stent implantation without ultrasound guidance and with replacement of concentional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. Circulation 94:1519, 1996
22. Schühlen H, Hadamitzky M, Walter H, Ulm K, Schömig A: Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Shatz stent placement. Circulation 97:2015, 1997
23. Sakariassen KS, Baumgartner HR: Axial dependence of platelet-collagen interactions in flowing blood. Upstream thrombus growth impairs downstream platelet adhesion. Arteriosclerosis 9:33, 1989
24. Sakariassen KS, Weiss HJ, Baumgartner HR: Upstream thrombus growth impairs downstream thrombogenesis in non-anticoagulated blood. Effect of procoagulant artery subendothelium and non procoagulant collagen. Thromb Haemost 65:596, 1991
25. Roald HE, Sakariassen KJ: Axial dependence of collagen-induced thrombus formation in flowing non-anticoagulated human blood. Anti-platelet drugs impair thrombus growth and increase platelet-collagen adhesion. Thromb Haemost 73:126, 1995
26. Ruggeri ZM: Mechanisms initiating platelet thrombus formation. Thromb Haemost 78:611, 1997
27. Sakariassen KS, Roald HE, Salatti JA: Ex vivo models for studying thrombosis: Special emphasis on shear rate dependent blood-collagen interactions, in Hwang NHC, Turitto VT, Yen MRT (eds): Advances in Cardiovascular Engineering. New York, NY, Plenum, 1992, p151
28. Béguin S, Kumar R: Thrombin, fibrin and platelets: A resonance loop in which von Willebrand factor is a necessary link. Thromb Haemost 78:590, 1997
29. Orvim U, Barstad RM, Vlasuk GP, Sakariassen KS: Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Arterioscler Thromb 15:2188, 1995
30. R) in an experimental model of human venous thrombosis. Thromb Haemost 74:1286, 1995
31. Sakariassen KS, Orning L, Stormorken H: Role of ADP and thromboxanes in human thrombus formation in ex vivo models. Platelets 8:385, 1997
32. Hanson SR, Sakariassen KS: Blood flow and antithrombotic drug effects. Am Heart J (in press)
33. Gast AG, Tschopp TB, Baumgartner HR: Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arterioscler Thromb 14:1466, 1994
34. Defreyn G, Bernat A, Delebassée D, Maffrand JP: Pharmacology of ticlopidine: A review. Semin Thromb Haemost 65:186, 1989
35. Kuzniar J, Splawinska B, Malinga K, Mazurek AP, Slapwinski J: Pharmacodynamics of ticlopidine: Relation between dose and time of administration to platelet inhibition. Int J Clin Pharmacol Ther 34:357, 1996
36. Caprie Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic event (CAPRIE). Lancet 138:1329, 1996